References
legend: design of the trial.(Individual percentage changes in PPi, comparing the end of the placebo phase and the end of the lansoprazole phase. 20.2% (2.7–31.5%).Clinical characteristics of patients.Data are showed as mean ± SD or N (%). Abbreviation: ABI, ankle–brachial index.Laboratory parameters in the final visits according to the phase of therapy.Abbreviations: PTH, parathyroid hormone; PPi, plasma inorganic pyrophosphate; ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase; TNAP, tissue-nonspecific alkaline phosphatase; CXCL4, platelet factor 4.